Notice of Proposed Sale · 144
Oruka Therapeutics, Inc.
ORKANASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Oruka Therapeutics, Inc.
- Issuer CIK
- 0000907654
- SEC file number
- 000-22873
- Phone
- 6506067910
- Person for whose account securities are to be sold
- PAUL QUINLAN
- Relationships to issuer
- Officer
- Street
- 855 Oak Grove Avenue Suite 100
- City
- Menlo Park
- State / country code
- CA
- Postal code
- 94025
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 71,000 | 7,676,520.00 | 66,209,699 | 08/14/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/14/2026 | Exercise of Stock Options | Issuer | 71,000 | N | 08/14/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| PAUL QUINLAN | Common | 06/15/2026 | 733 | 51,082.77 |
Seller — prior-sale row 1, entry 1
- Name
- PAUL QUINLAN
- Street
- 855 Oak Grove Avenue Suite 100
- City
- Menlo Park
- State / country code
- CA
- Postal code
- 94025
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Notice signature
- Notice date
- 08/14/2026
- Signed
- /s/ Paul Quinlan
- Plan adoption dates
- 05/15/2026
Company context
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.